Drug Safety update
December 2014: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
Recombinant human granulocyte-colony stimulating factor stimulates the production of neutrophils and may reduce the duration of chemotherapy-induced neutropenia and so reduce the incidence of sepsis. There is no evidence that it improves overall survival.
Granulocyte-colony stimulating factors should only be prescribed by those experienced in their use. For Haematology and Oncology only.
Monitor blood counts, including differential white cell and platelet counts. Treatment should be withdrawn in patients who develop signs of pulmonary infiltration.
Monitor spleen size as splenic rupture has been reported.